Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VA2914 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| VA2914 | DRUG | - |
Inclusion Criteria: * women in good general health with regular, ovulatory menstrual cycles * age 18-35 * not pregnant * not sexually active or reliably use barrier methods of contraception * normal liver and renal functions and normal laboratory exams Exclusion Criteria: * pregnant or breastfeed...
VA2914 is an investigational small molecule being studied for contraception. It is a progesterone receptor modulator under development by Perrigo Company plc (PRGO). The drug is intended for use in women, with clinical research focused on low dose continuous administration for contraceptive purposes.
VA2914 is a progesterone receptor modulator. It acts on the progesterone receptor to modulate its activity, which is relevant to its intended use in contraception. The drug is being studied for its effects on the reproductive system in women.
VA2914 is being developed by Perrigo Company plc, a pharmaceutical company traded on the stock exchange under the ticker PRGO. The company is conducting clinical research on this drug for the indication of contraception.
VA2914 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for contraception.
VA2914 has one completed Phase 2 clinical trial, identified as NCT00456924, titled "Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914." The trial enrolled 48 healthy female participants aged 18 years and older, and was conducted in Belgium and France.
VA2914 is also known by its chemical name as a progesterone receptor modulator. No other alternative names for this drug have been disclosed in the available clinical trial information, so it is primarily referred to as VA2914 in research contexts.